Similar articles

• Liposomes as immunological adjuvants: approaches to immunopotentiation including ligand-mediated targeting to macrophages.

  Gregoriadis G. Gregoriadis G. Res Immunol. 1992 Feb;143(2):178-85. doi: 10.1016/s0923-2494(92)80161-d. Res Immunol. 1992. PMID: 1574643 Review. No abstract available.
• Liposomes containing lipid A as a potent non-toxic adjuvant.

  Alving CR, Verma JN, Rao M, Krzych U, Amselem S, Green SM, Wassef NM. Alving CR, et al. Res Immunol. 1992 Feb;143(2):197-8. doi: 10.1016/s0923-2494(92)80165-h. Res Immunol. 1992. PMID: 1574647 Review. No abstract available.
• The macrophage as the principal antigen-presenting cell for liposome-encapsulated antigen.

  Szoka FC Jr. Szoka FC Jr. Res Immunol. 1992 Feb;143(2):186-8. doi: 10.1016/s0923-2494(92)80162-e. Res Immunol. 1992. PMID: 1574644 Review. No abstract available.
• Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.

  Nikoofal-Sahlabadi S, Matbou Riahi M, Sadri K, Badiee A, Nikpoor AR, Jaafari MR. Nikoofal-Sahlabadi S, et al. Eur J Pharm Sci. 2018 Jul 1;119:159-170. doi: 10.1016/j.ejps.2018.04.018. Epub 2018 Apr 13. Eur J Pharm Sci. 2018. PMID: 29660463
• Correction of defective tumoricidal activity of macrophages from A/J mice by liposomal immunomodulators.

  Phillips NC, Skamene E, Chedid L. Phillips NC, et al. Immunopharmacology. 1988 Jan-Feb;15(1):1-10. doi: 10.1016/0162-3109(88)90037-9. Immunopharmacology. 1988. PMID: 3360595